Product Description
EDP-239 is Enantas lead NS5A inhibitor for HCV infection
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Enanta
Company Location: WATERTOWN MA 02472
Company CEO: Jay R. Luly
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Hepatitis C|Hepatitis A
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| CEDP239X2201 | P1 |
Completed |
Hepatitis A|Hepatitis C |
2014-11-01 |
2022-09-20 |
Primary Endpoints|Treatments |
|
| CDEB025A2119 | P1 |
Completed |
Hepatitis C |
2014-11-01 |
2022-09-20 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|